Trupanion: The Stock Has Already Fallen as Far as the Old Story Will Let It. The Numbers Are Telling a Different One.

The market is still pricing Trupanion as a company that can't make its economics work. The stock is down roughly 50% over the past 12 months and has spent most of that time trading well below its 52-week high of $51.78. It closed yesterday at $24.32.

Then it reported second-quarter results, beat earnings by about 40%, guided to adjusted operating income of $176 million to $184 million for the full year, and authorized a $100 million share repurchase alongside a $44 million extraordinary dividend. The stock rose 6.7% after hours. The tape move was modest, and it should be - because the real setup isn't about what happened yesterday. It's about whether the market will keep treating this like a falling business when the financial bridge already points the other way.

The Old Story

Trupanion sells pet insurance. The business model is simple: collect subscription premiums, pay veterinary claims, keep the spread. But the spread has been the problem. For years the company lost money on a GAAP basis because it had to spend heavily to acquire new pet policies - often $300 or more per enrollment - and the economics only stabilized once a pet stayed insured long enough. Vet inflation has run at double-digit levels, claims costs stayed elevated, and the company never seemed to find a consistent path to profitability.

That's the story the market anchored to. A business burning cash to buy customers it struggled to keep profitable. The stock price tells you how much conviction that narrative carried.

The Proof Path

The numbers from the first half of 2026 don't look like the old story anymore.

Revenue grew 12% in the first half to $777 million, and the second quarter alone came in at $392.9 million, up 11% year over year. Subscription revenue - the core insurance business - grew 14%, reaching $276.7 million. More importantly, the margin mechanics are accelerating. Gross profit is growing at 20.9% year over year, well ahead of the 11.8% revenue growth rate. That gap between top-line growth and gross profit growth is operating leverage. It means each incremental dollar of premium costs less to underwrite than the last one.

Subscription adjusted operating income (which strips out acquisition costs so you can see the underlying economics of the active policy base) hit $41.4 million in Q2, up 24% year over year. The subscription AOI margin expanded to 15% from 13.8%. Management said combined fixed and variable spending fell to 14.8% of subscription revenue from 15.1%.

The lifetime value of an enrolled pet jumped 25% during the quarter. Pet retention ticked up to 98.37%. Gross pet adds rose 9%, and net subscription pets added surged 39% to about 18,800. The company ended the quarter with 1.125 million enrolled subscription pets.

On the cash side, free cash flow for the trailing twelve months stands at $82.2 million, up 34% year over year. Q2 alone delivered $19.2 million in free cash flow, up from $12 million a year earlier. The company sits on $398.5 million in cash and short-term investments against $106.9 million in debt - a net cash position of roughly $292 million.

Management guided to full-year 2026 revenue of $1.584 billion to $1.601 billion (about 11% growth at the midpoint) and total adjusted operating income of $176 million to $184 million, up roughly 19% year over year. Earnings per share in the first half came in at $0.27 combined, well above the consensus range of roughly $0.19.

The capital return package is worth underscoring: a $100 million open-ended buyback and a $44 million extraordinary dividend from the insurance subsidiary. That's $144 million of capital return - roughly 13.5% of market capitalization - funded from a business that already has a net cash balance. It is not a signal you give when you're worried about the runway.

Why the Market Still Doesn't Feel Comfortable

There's a reason the stock has not run hard off the quarter. Adjusted operating income and GAAP operating income are not the same thing, and the gap is large. Trupanion's GAAP operating margin sits at 1.6%, roughly 10 percentage points below its adjusted operating income margin of 11.1% to 11.6%. The adjustment removes acquisition costs - the money spent on marketing, sales commissions, and onboarding to bring in new policies.

That's not a trivial omission. Acquisition costs are real cash outflows, and pet acquisition costs did rise to $299 per pet from $276 a year earlier. If growth slows and the company has to spend more to replace lapsing policies, those costs reappear on the GAAP statement.

The vet inflation headwind is also real. The cost of paying veterinary invoices as a share of subscription revenue was 70.2%, compared to 71.1% in the prior-year quarter. Double-digit vet inflation is running higher than management's historical expectations.

These risks aren't illusory. But they don't erase the direction of travel. Gross profit is growing at nearly twice the rate of revenue. Retention is above 98%. The lifetime value of a pet jumped a quarter. And free cash flow is up 34% on a $82 million trailing run rate with room to accelerate.

The Financial Bridge

Here's the simple path. Trupanion is guiding to $176 million to $184 million in adjusted operating income for 2026. Even if you discount the adjusted number and focus on what converts to cash, the free cash flow trajectory is the anchor. TTM free cash flow is $82.2 million. If FCF grows at a 25% clip in 2027 - a conservative rate given this quarter's 34% pace and the margin expansion still working through - that puts next-year FCF in the range of $100 million to $107 million.

The company has roughly 43.6 million shares outstanding. A $100 million buyback would retire about 9.4% of those. If you apply a 10x to 12x free cash flow multiple - a range that reflects a subscription business with 11% revenue growth, improving margins, and a dominant market position - the implied value sits between $23 and $29 per share at today's share count, and higher if the buyback executes.

The enterprise value is $790 million. Revenue at $1.59 billion puts the EV/sales multiple at 0.5x. That is a multiple usually reserved for companies the market expects to keep losing money. This one has delivered five consecutive quarters of positive net income and $82 million in trailing free cash flow.

The market is pricing the old risk profile. The operating setup is already getting cleaner.

What Would Break the Setup

Vet inflation accelerating further and forcing the claims ratio to deteriorate below 70%. That would compress the gross margin trajectory management is counting on. A meaningful drop in retention below 97% would undermine the lifetime value improvement and force heavier reinvestment into acquisition. Either of those would slow the margin expansion and keep GAAP profitability at bay.

If acquisition costs keep rising while net pet adds stall, the business reverts to the old cycle: spend more to stay flat. That's the condition I'd watch. The tripwire is a quarter where subscription AOI margin contracts below 14% while revenue growth falls below 8%. That would suggest the operating leverage thesis is fracturing rather than building.

Until then, the numbers say this is a subscription business with growing free cash flow, a net cash balance, a 13.5% market-cap buyback, and margins that are already expanding. The stock has done the work of resetting expectations. The operating evidence hasn't broken. The gap between the two is what the setup is built on.